Novartis announced it broke ground for the expansion of its biopharmaceutical manufacturing plant in Singapore. The USD 256 million investment will facilitate Novartis in deploying digital and automation solutions to enhance manufacturing productivity, improve operational efficiency, and upskill the workforce. The expanded site will focus on manufacturing therapeutic antibody drugs to deliver breakthrough treatments to patients globally.

This endeavour will enhance the skills of Novartis' current workforce and is poised to create 100 high skilled new job openings, fostering the expansion of the local life science sector. Novartis acknowledges the significance of investing in talent, and the expanded facility will not only bring in new team members but also provide training for existing employees to thrive in a highly digitalized and automated setting.